{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25+mg+diphenhydramine+IV", "query": { "intervention": "25 mg diphenhydramine IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 53, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=25+mg+diphenhydramine+IV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-09T01:14:40.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02858310", "title": "E7 TCR T Cells for Human Papillomavirus-Associated Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Papillomavirus Infections", "Cervical Intraepithelial Neoplasia", "Carcinoma In Situ", "Vulvar Neoplasms", "Vulvar Diseases" ], "interventions": [ { "name": "E7 TCR cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Chest CT and MRI or PET", "type": "DIAGNOSTIC_TEST" }, { "name": "PFT", "type": "DIAGNOSTIC_TEST" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Droperidol", "type": "DRUG" }, { "name": "Prochlorperazine", "type": "DRUG" }, { "name": "Diphenoxylate HCL", "type": "DRUG" }, { "name": "Atropine sulfate", "type": "DRUG" }, { "name": "Codeine sulfate", "type": "DRUG" }, { "name": "Loperamide", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine HCL", "type": "DRUG" }, { "name": "Hydroxyzine HCL", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 224, "start_date": "2017-01-27", "completion_date": "2025-07-02", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858310" }, { "nct_id": "NCT01474915", "title": "Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Nausea and Vomiting (PONV)", "Nausea" ], "interventions": [ { "name": "Aprepitant", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sergio Bergese", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 122, "start_date": "2007-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-12-03", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01474915" }, { "nct_id": "NCT00176475", "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2005-01", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176475" }, { "nct_id": "NCT04862221", "title": "TReatment for ImmUne Mediated PathopHysiology", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Liver Failure", "Fulminant Hepatic Failure", "Hepatic Encephalopathy", "Acute Liver Injury", "Immune Dysregulation" ], "interventions": [ { "name": "High-dose methylprednisolone", "type": "DRUG" }, { "name": "Equine anti-thymocyte globulin", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Placebo for prednisolone", "type": "DRUG" }, { "name": "Placebo for infusions", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 44, "start_date": "2022-02-09", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 17, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862221" }, { "nct_id": "NCT02552394", "title": "J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "huJ591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2015-07", "completion_date": "2021-01-03", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552394" }, { "nct_id": "NCT04668833", "title": "ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor Malignancies" ], "interventions": [ { "name": "Autologous lymphocyte infusion (ALI)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2020-09-29", "completion_date": "2025-10-24", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04668833" }, { "nct_id": "NCT00787761", "title": "Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic HSCT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 24, "start_date": "2007-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787761" }, { "nct_id": "NCT02972502", "title": "Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Headache, Migraine" ], "interventions": [ { "name": "Metoclopramide", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" }, { "name": "Diphenhydramine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OhioHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-02", "completion_date": "2017-04-24", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02972502" }, { "nct_id": "NCT05896228", "title": "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Multiple Myeloma", "Relapsed Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benjamin T Diamond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2024-02-20", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896228" }, { "nct_id": "NCT01729494", "title": "Belatacept Early Steroid Withdrawal Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "rabbit antithymocyte globulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "early cessation of steroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-09", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-09T01:14:40.887Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729494" } ] }